Contact
searchSearch
HMP Global
Login

Oncology

Featured

Conference Coverage
Durvalumab Plus Olaparib Demonstrates Strong Clinical Promise for Metastatic Pancreatic Cancer
01/12/2026
Stephanie Holland
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study...
01/12/2026
Oncology
Conference Coverage
First-Line Nivolumab Plus Ipilimumab for Patients With Unresectable Hepatocellular Carcinoma: CheckMate 9DW 4-Year Follow-Up
01/12/2026
Stephanie Holland
Updated results from the phase 3 CheckMate 9DW trial show that first-line nivolumab plus ipilimumab continues to demonstrate sustained clinical efficacy with a manageable safety profile among patients with unresectable hepatocellular...
Updated results from the phase 3 CheckMate 9DW trial show that first-line nivolumab plus ipilimumab continues to demonstrate sustained clinical efficacy with a manageable safety profile among patients with unresectable hepatocellular...
Updated results from the phase 3...
01/12/2026
Oncology
Conference Coverage
Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial,...
01/12/2026
Oncology
News
Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial...
01/12/2026
Oncology
Conference Coverage
Atezolizumab Plus FOLFIRINOX and Bevacizumab Improves PFS Over Atezolizumab Alone for dMMR/MSI-H Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial...
01/12/2026
Oncology
Quiz
Chidamide Plus Azacitidine Maintenance Therapy for AML
01/12/2026
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following allogeneic hematopoietic stem cell transplantation, dual epigenetic maintenance therapy with chidamide and azacitidine demonstrated promising activity and acceptable tolerability for patients with high-risk acute...
True or false: Following...
01/12/2026
Oncology
Ibrahim Aldoss, MD
Videos
Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
01/12/2026
Ibrahim Aldoss, MD
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared...
01/12/2026
Oncology
News
Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes
01/12/2026
Emily Estrada
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine...
01/12/2026
Oncology
News
Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for R/R Acute Myeloid Leukemia
01/12/2026
Emily Estrada
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax...
01/12/2026
Oncology
Conference Coverage
Pharmacogenomic Assay ToxNav Advantage Launches in the US to Assess Fluoropyrimidine Toxicity Risk
01/09/2026
Stephanie Holland
Mira Precision Health has announced the US launch of a new pharmacogenomic assay to identify patients receiving fluoropyrimidine-based chemotherapy, including 5-fluorouracil and capecitabine, who may be at increased risk of severe...
Mira Precision Health has announced the US launch of a new pharmacogenomic assay to identify patients receiving fluoropyrimidine-based chemotherapy, including 5-fluorouracil and capecitabine, who may be at increased risk of severe...
Mira Precision Health has...
01/09/2026
Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Conference Coverage
Teclistamab Plus Talquetamab Shows Deep and Durable Responses for Extramedullary Multiple Myeloma: RedirecTT-1
01/08/2026
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP,...
01/08/2026
Oncology

Videos

Ibrahim Aldoss, MD
Videos
Azacitidine Plus Venetoclax Shows Superior Efficacy Compared With Intensive Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia
01/12/2026
Ibrahim Aldoss, MD
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared results from the phase 2 PARADIGM trial which showed frontline azacitidine plus venetoclax significantly improved survival, response rates, and quality of life compared with intensive chemotherapy for AML.
Ibrahim Aldoss, MD, shared...
01/12/2026
Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Conference Coverage
Teclistamab Plus Talquetamab Shows Deep and Durable Responses for Extramedullary Multiple Myeloma: RedirecTT-1
01/08/2026
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP,...
01/08/2026
Oncology
John Burke, MD
Conference Coverage
Subcutaneous Mosunetuzumab Demonstrates Deep, Early Responses for Treatment-Naïve Follicular Lymphoma: Phase 2 MorningSun Trial
01/08/2026
John Burke, MD, reported that subcutaneous mosunetuzumab achieved high response rates and durable remissions with manageable toxicity for treatment-naïve, high-tumor burden follicular lymphoma.
John Burke, MD, reported that subcutaneous mosunetuzumab achieved high response rates and durable remissions with manageable toxicity for treatment-naïve, high-tumor burden follicular lymphoma.
John Burke, MD, reported that...
01/08/2026
Oncology
Stephen Schuster, MD
Conference Coverage
5-Year Data Show Durable Remissions With Tisagenlecleucel for R/R Follicular Lymphoma: ELARA Trial
01/08/2026
Stephen Schuster presented updated results from the phase 2 ELARA study which evaluated tisagenlecleucel among patients with relapsed/refractory follicular lymphoma.
Stephen Schuster presented updated results from the phase 2 ELARA study which evaluated tisagenlecleucel among patients with relapsed/refractory follicular lymphoma.
Stephen Schuster presented...
01/08/2026
Oncology
David Andorsky, MD
Conference Coverage
Novel Allosteric BCR::ABL1 Inhibitor TERN-701 Demonstrates Encouraging Efficacy for Chronic Myeloid Leukemia: CARDINAL Study
01/05/2026
David Andorsky, MD, presented early results from the phase 1/2 CARDINAL study which evaluated TERN-701 for patients with heavily pretreated chronic myeloid leukemia, at the 2025 ASH Annual Meeting & Exposition.
David Andorsky, MD, presented early results from the phase 1/2 CARDINAL study which evaluated TERN-701 for patients with heavily pretreated chronic myeloid leukemia, at the 2025 ASH Annual Meeting & Exposition.
David Andorsky, MD, presented...
01/05/2026
Oncology
Matthew Davids, MD
Conference Coverage
Genetic Risk Factors May Help Predict Richter Transformation in Chronic Lymphocytic Leukemia
01/05/2026
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights advances in identifying and managing Richter transformation among patients with chronic lymphocytic leukemia.
Matthew Davids, MD, highlights...
01/05/2026
Oncology
Joseph Mikhael, MD
Conference Coverage
Optimizing Sequencing of CAR T-Cell and Bispecific Therapies to Improve Multiple Myeloma Outcomes
01/05/2026
Joseph Mikhael, MD, MEd, FRCPC
Joseph Mikhael, MD, explains the importance of strategic sequencing and safety optimization for multiple myeloma immunotherapies.
Joseph Mikhael, MD, explains the importance of strategic sequencing and safety optimization for multiple myeloma immunotherapies.
Joseph Mikhael, MD, explains the...
01/05/2026
Oncology
Headshot of Dr Cassie Kline
Videos
Tovorafenib Maintains Durable Clinical Benefit in Relapsed/Refractory Pediatric Low-Grade Glioma: Part 1
01/02/2026
Cassie Kline, MD, MAS
01/02/2026
Oncology
Headshot of Dr Cassie Kline
Videos
Tovorafenib Maintains Durable Clinical Benefit in Relapsed/Refractory Pediatric Low-Grade Glioma: Part 2
01/02/2026
Cassie Kline, MD, MAS
01/02/2026
Oncology
Adriana Rossi, MD
Conference Coverage
Emerging Patterns of Delayed CAR T-Cell Therapy Toxicities
01/02/2026
Adriana Rossi, MD, discussed the importance of monitoring for delayed CAR T-cell therapy toxicities such as neurotoxicity, colitis, and prolonged cytopenias as treatment use for patients expands, at the 2025 Lymphoma, Leukemia & Myeloma...
Adriana Rossi, MD, discussed the importance of monitoring for delayed CAR T-cell therapy toxicities such as neurotoxicity, colitis, and prolonged cytopenias as treatment use for patients expands, at the 2025 Lymphoma, Leukemia & Myeloma...
Adriana Rossi, MD, discussed the...
01/02/2026
Oncology

Insights From the ASCO Annual Meeting

Raajit Rampal, MD, PhD
Conference Coverage
Pacritinib Therapy May Improve Hemoglobin Responses Among Patients With Myelofibrosis
09/03/2025
Raajit Rampal, MD, PhD
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares results from a real-world analysis evaluating outcomes and hemoglobin responses among patients with myelofibrosis who were treated with pacritinib.
Raajit Rampal, MD, PhD shares...
09/03/2025
Oncology
John Strickler, MD
Videos
Addition of FOLFIRI to Sotorsaib and Panitumumab Demonstrates Long-Term Efficacy, Safety Among Patients With KRAS G12C-Mutated Metastatic Colorectal Cancer
08/21/2025
John Strickler, MD
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses results from the CodeBreaK 101 study which assessed the addition of FOLFIRI to sotorasib and panitumumab among patients with KRAS G12C-mutated metastatic colorectal cancer.
John Strickler, MD, discusses...
08/21/2025
Oncology
Amer Zeidan, MBBS, MHS
Conference Coverage
Decitabine-Cedazuridine Plus Venetoclax Therapy Shows Efficacy and Safety for Patients With Newly Diagnosed AML
08/20/2025
Amer Zeidan, MBBS
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares results from a phase 2 trial determining the safety and efficacy of decitabine-cedazuridine plus venetoclax for patients with newly diagnosed acute myeloid leukemia ineligible for induction chemotherapy.
Amer Zeidan, MBBS, MHS, shares...
08/20/2025
Oncology
Meghan Mooradian, MD
Conference Coverage
Neoadjuvant Dostarlimab Plus Cobolimab Demonstrates Promise Among Patients With High-Risk Resectable Melanoma
08/12/2025
Meghan Mooradian, MD
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses primary analysis results from the phase 2 NEO-MEL-T trial, which showed that neoadjuvant dostarlimab plus cobolimab demonstrated promising efficacy and safety among patients with high-risk resectable melanoma.
Meghan Mooradian, MD, discusses...
08/12/2025
Oncology
Nick James, MD, PhD
Conference Coverage
Use of a Multimodal Artificial Intelligence Algorithm in High-Risk Non-Metastatic Prostate Cancer
08/12/2025
Nicholas James, MD
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses results from a study which assessed using a multimodal artificial intelligence algorithm to identify patients with high-risk non-metastatic prostate cancer who are most likely to benefit from adding a...
Nick James, MD, PhD, discusses...
08/12/2025
Oncology
Stephen Bagley, MD
Conference Coverage
Intracerebroventricular Delivery of CART-EGFR-IL13Rα2 Demonstrates Promise Among Patients With Recurrent Glioblastoma
08/05/2025
Stephen Bagley, MD
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses...
08/05/2025
Oncology
Zeynep Eroglu, MD
Conference Coverage
First-Line Encorafenib Plus Binimetinib and Nivolumab for Patients With BRAF-Mutated Melanoma Brain Metastases
07/24/2025
Zeynep Eroglu, MD
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses results from the SWOG S2000 study which demonstrated that encorafenib plus binimetinib and nivolumab significantly improved progression-free survival compared to ipilimumab plus nivolumab among patients with...
Zeynep Eroglu, MD, discusses...
07/24/2025
Oncology
Herbert Loong, MD
Conference Coverage
BAY 2927088 Demonstrates Promise Among Patients With HER2-Mutated Non-Small Cell Lung Cancer
07/24/2025
Herbert Loong, MD
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses results from the SOHO-01 trial which showed that BAY 2927088 demonstrated promising efficacy and safety among patients with HER2-mutated non-small cell lung cancer.
Herbert Loong, MD, discusses...
07/24/2025
Oncology
Georgina Long, MD, PhD
Conference Coverage
Addition of Relatimab to Nivolumab Did Not Significantly Improve Outcomes for Patients With Melanoma
07/24/2025
Georgina Long, MBBS, PhD
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD, discusses primary results from the RELATIVITY-098 trial, which demonstrated that adjuvant nivolumab plus relatimab did not significantly improve outcomes compared to adjuvant nivolumab monotherapy among patients with...
Georgina Long, MD, PhD,...
07/24/2025
Oncology
Alexander van Akkooi, MD, PhD
Conference Coverage
Adjuvant Encorafenib Plus Binimetinib Demonstrates Promise Among Patients With BRAF-Mutated Melanoma
07/24/2025
Alexander Van Akkooi, MD, PhD
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD, discusses primary analysis results from the EORTC 2139-MG/Columbus-AD trial which demonstrated that adjuvant encorafenib plus binimetinib demonstrates clinical promise among patients with BRAF-mutated melanoma.
Alexander Van Akkooi, MD, PhD,...
07/24/2025
Oncology

Insights From the ESMO Congress

Stephen Freedland, MD
Videos
Enzalutamide Plus Androgen Deprivation Therapy in Biochemically Recurrent Prostate Cancer
12/02/2025
Stephen J. Freedland, MD
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses final overall survival results from the EMBARK study, which evaluated enzalutamide plus androgen deprivation therapy in patients with high-risk biochemical recurrence and negative conventional imaging.
Stephen Freedland, MD, discusses...
12/02/2025
Oncology
Brian Slomovitz, MD
Videos
Relacorilant Plus Nab-Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer
12/02/2025
Brian M. Slomovitz, MD, MS
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses updated findings from the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
Brian Slomovitz, MD, discusses...
12/02/2025
Oncology
Pasi Jänne, MD, PhD
Videos
Osimertinib Plus Chemotherapy Provides Broad Survival Benefit in EGFR-Mutant NSCLC
12/02/2025
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses subgroup analysis results from the FLAURA2 trial evaluating osimertinib plus platinum-pemetrexed chemotherapy in patients with newly diagnosed EGFR-mutant non-small cell lung cancer.
Pasi Jänne, MD, PhD, discusses...
12/02/2025
Oncology
David Goldstein, MD
Videos
Regorafenib Plus Nivolumab Fails to Improve Outcomes in Gastric or Gastroesophageal Cancer
12/02/2025
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses results from the INTEGRATE study which assessed regorafenib plus nivolumab in previously treated patients with gastric or gastroesophageal cancer.
David Goldstein, MD, discusses...
12/02/2025
Oncology
Sara Lonardi, MD
Videos
Dual Immunotherapy Delivers Durable Benefit in MSI-H/dMMR Metastatic Colorectal Cancer
11/13/2025
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated results from CheckMate 8HW comparing nivolumab plus ipilimumab with nivolumab alone or chemotherapy as first-line therapy for patients with MSI-H/dMMR metastatic colorectal cancer.
Sara Lonardi, MD, shares updated...
11/13/2025
Oncology
Sanjay Popat, MD, PhD
Videos
First-Line Zongertinib Demonstrates Promise in HER2-Mutated NSCLC
11/13/2025
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses results from the phase 2 BEAMION-LUNG 1 trial evaluating zongertinib as a first-line treatment option for patients with advanced HER2-mutated non-small cell lung cancer.
Sanjay Popat, MD, PhD, discusses...
11/13/2025
Oncology
Janice Mehnert, MD
Videos
Pembrolizumab Lowers Distant Recurrence Risk in Resected Merkel Cell Carcinoma
11/10/2025
Janice Mehnert, MD
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses results from the phase 3 STAMP trial evaluating pembrolizumab versus observation in patients with resected merkel cell carcinoma.
Janice Mehnert, MD, discusses...
11/10/2025
Oncology
Nima Nabavizadeh, MD
Videos
MCED Blood Test Detects Cancer Early With High Accuracy
11/10/2025
Nima Nabavizadeh, MD
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses results from the registrational phase 2 PATHFINDER-2 study evaluating an MCED multi-cancer early detection blood test in an intended-use population.
Nima Nabavizadeh, MD, discusses...
11/10/2025
Oncology
Maria De Santis, MD
Videos
Addition of Durvalumab Strengthens Treatment for Patients With High-Risk Non–Muscle Invasive Bladder Cancer
11/10/2025
Maria De Santis, MD
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses results from the phase 3 POTOMAC trial evaluating the addition of durvalumab to bacillus Calmette-Guérin induction and maintenance therapy among patients with high-risk non-muscle invasive bladder cancer.
Maria De Santis, MD, discusses...
11/10/2025
Oncology
Dean Fennell, MD, PhD
Videos
Intratumor Heterogeneity Predicts Niraparib Benefit in Relapsed Mesothelioma
11/10/2025
Dean Fennell, MD, PhD
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses results from the investigator-initiated phase 2 NERO trial evaluating niraparib plus active symptom control versus active symptom control alone in patients with relapsed mesothelioma.
Dean Fennell, MD, PhD, discusses...
11/10/2025
Oncology

Live Meetings

Recent News

Conference Coverage
Durvalumab Plus Olaparib Demonstrates Strong Clinical Promise for Metastatic Pancreatic Cancer
01/12/2026
Stephanie Holland
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study show that durvalumab plus olaparib therapy demonstrates strong clinical promise among patients with DNA damage repair-altered metastatic pancreatic cancer.
Results from a phase 2 study...
01/12/2026
Oncology
Conference Coverage
First-Line Nivolumab Plus Ipilimumab for Patients With Unresectable Hepatocellular Carcinoma: CheckMate 9DW 4-Year Follow-Up
01/12/2026
Stephanie Holland
Updated results from the phase 3 CheckMate 9DW trial show that first-line nivolumab plus ipilimumab continues to demonstrate sustained clinical efficacy with a manageable safety profile among patients with unresectable hepatocellular...
Updated results from the phase 3 CheckMate 9DW trial show that first-line nivolumab plus ipilimumab continues to demonstrate sustained clinical efficacy with a manageable safety profile among patients with unresectable hepatocellular...
Updated results from the phase 3...
01/12/2026
Oncology
Conference Coverage
Encorafenib and Cetuximab Plus FOLFIRI Demonstrates Superior Response Rates for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial, first-line treatment with encorafenib plus cetuximab and FOLFIRI improved response rates compared to standard chemotherapy for BRAF V600E-mutant metastatic colorectal cancer, with manageable toxicity.
In the BREAKWATER trial,...
01/12/2026
Oncology
News
Circulating Tumor DNA-Guided Cetuximab Rechallenge Shows Improved Outcomes for Select Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial demonstrated the benefit of comprehensive molecular stratification to predict the efficacy of anti-EGFR drug rechallenge strategies for certain patients with RAS/BRAF wild-type metastatic colorectal cancer.
Data from the CAVE-2 GOIM trial...
01/12/2026
Oncology
Conference Coverage
Atezolizumab Plus FOLFIRINOX and Bevacizumab Improves PFS Over Atezolizumab Alone for dMMR/MSI-H Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial...
01/12/2026
Oncology
News
Decitabine Plus Cedazuridine Maintenance Therapy Shows Promising Survival Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndromes
01/12/2026
Emily Estrada
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine and cedazuridine maintenance therapy demonstrated promising activity with manageable toxicity for patients with very high-risk acute myeloid leukemia or myelodysplastic syndrome.
The combination of decitabine...
01/12/2026
Oncology
News
Venetoclax Plus CACAG Regimen Demonstrates High Response Rates and Favorable Survival for R/R Acute Myeloid Leukemia
01/12/2026
Emily Estrada
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax and chidamide, azacitidine, cytarabine, aclarubicin, G-CSF therapy demonstrated high complete response rates, encouraging 1-year survival outcomes, and manageable toxicity for patients with R/R AML.
The combination of venetoclax...
01/12/2026
Oncology
Conference Coverage
Pharmacogenomic Assay ToxNav Advantage Launches in the US to Assess Fluoropyrimidine Toxicity Risk
01/09/2026
Stephanie Holland
Mira Precision Health has announced the US launch of a new pharmacogenomic assay to identify patients receiving fluoropyrimidine-based chemotherapy, including 5-fluorouracil and capecitabine, who may be at increased risk of severe...
Mira Precision Health has announced the US launch of a new pharmacogenomic assay to identify patients receiving fluoropyrimidine-based chemotherapy, including 5-fluorouracil and capecitabine, who may be at increased risk of severe...
Mira Precision Health has...
01/09/2026
Oncology
Conference Coverage
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
Conference Coverage
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use